Telix sets up subsidiary to make and trial radio-labelled meds in Japan

By Gareth Macdonald

- Last updated on GMT


Related tags Medicine

Radiopharmaceuticals firm Telix Pharmaceuticals Limited has established a subsidiary in Japan to support clinical development and manufacturing activities.

Melbourne, Australia-based Telix announced its new Kyoto operation this week, also revealing it has hired two executives - Shintaro Nishimura and Takeshi Oka - as president and chief medical officer, respectively.

CEO Christian Behrenbruch told in-Pharmatechnologist there is significant demand for Telix’s products in Japan, partly due to the country’s changing demographic profile.

As a market, Japan is probably the second largest homogeneous market after the US for our products.

There is a lot of government and academic momentum around radiopharmaceuticals in Japan, both diagnostic and therapeutic, given the aging nature of the population​,” he added.

Behrenbruch described Telix’s candidates as “targeted radiation products” explaining they can “both image and treat patients either by changing the dose or swapping the isotope on the same targeting agent​.”

Radiopharmaceutical manufacturing

In December, Telix formed a manufacturing partnership with JFE Engineering Corporation, a Yokohama-based engineering services firm that operates in the areas of energy and environment, urban infrastructure and industrial machinery.

The agreement will initially focus on the feasibility assessment for producing TLX-250 (girentuximab), an antibody-based agent for diagnosis of clear cell renal cell carcinoma, for the Japanese market.

According to Behrenbruch, “They (JFE) have built a state-of-the-art isotope production facility in Yokohama and we will be working with them closely to make our products available​.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more